A natural antibiotic
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Fidaxomycin

Item No. 15503

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(3E,5E,8S,9E,11S,12R,13E,15E,18S)-3-[[[6-deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-β-D-mannopyranosyl]oxy]methyl]-12-[[6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-β-D-lyxo-hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-oxacyclooctadeca-3,5,9,13,15-pentaen-2-one
CAS Number
873857-62-6
Synonyms
  • Clostomicin B1
  • Lipiarmycin
  • OPT-80
  • PAR-101
  • Tiacumicin B
Molecular Formula
C52H74Cl2O18
Formula Weight
1058.0
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 2 mg/mlDMSO: 2 mg/mlDMSO:PBS(pH7.2) (1:1): 0.5 mg/mlEthanol: 5 mg/ml
λmax
230, 268 nm
SMILES
O=C1/C(CO[C@H]2[C@@H](OC)[C@@H](O)[C@H](OC(C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)=O)[C@@H](C)O2)=C/C=C/C[C@H](O)/C(C)=C\[C@H](CC)[C@@H](O[C@]4([H])OC(C)(C)C(OC(C(C)C)=O)[C@H](O)[C@@H]4O)/C(C)=C\C(C)=C/C[C@]([C@H](O)C)([H])O1
InChi Code
InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,1
InChi Key
ZVGNESXIJDCBKN-KXVGEYJXSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $68

    Add

    50 mg

    $130

    Add

    100 mg

    $228

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Fidaxomycin is a natural macrocyclic antibiotic that inhibits RNA polymerase with selectivity for Gram-positive bacteria over Gram-negative bacteria (IC50s = 0.4 and 6 μM, respectively).1 It has potent antibacterial activity against most Gram-positive bacteria and effectively targets the Gram-positive C. difficile (MIC = 12 ng/ml).1 Orally administered fidaxomycin exhibits minimal systemic bioavailability resulting in maximal gastrointestinal tract distribution.1 Fidaxomycin is effective in clearing C. difficile infections while sparing Gram-negative bacteria in the gut.2,3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Srivastava, A., Talaue, M., Liu, S., et al. New target for inhibition of bacterial RNA polymerase: "Switch region". Curr. Opin. Microbiol. 14(5), 532-543 (2011).

    2. Louie, T.J., Emery, J., Krulicki, W., et al. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 53(1), 261-263 (2009).

    3. Louie, T.J., Miller, M.A., Mullane, K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364(5), 422-431 (2011).

    Product Citations

    Calán, A., García-Berejo, M.L., Troyano, A., et al. Stimulation of p38 mitogen-activated protein kinase is an early regulatory event for the cadmium-induced apoptosis in human promonocytic cells. The Journal of Biological Chemisty 275(15), 11418-11424 (2000).